Affinity DataIC50: 1.20E+3nMAssay Description:Binding affinity to KOP receptor (unknown origin) at 10 uMMore data for this Ligand-Target Pair
Affinity DataEC50: 1.50E+3nMAssay Description:Agonist activity at KOP receptor (unknown origin)More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: 2.00E+5nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: 3.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: 8.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: 3.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: 3.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: 2.00E+5nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: 8.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: 8.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: 2.00E+5nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: 5.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: 5.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: 8.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: 2.00E+5nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: 3.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: 5.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: 2.00E+5nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: 5.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: 5.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: 2.00E+5nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: 3.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: 2.00E+5nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: 5.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: 5.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: 2.00E+5nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: 3.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: 8.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: 3.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: 8.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: <2.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: 3.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: 3.00E+4nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair